Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Nurexone Biologic Inc (NRXBF)

Nurexone Biologic Inc (NRXBF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])

Fundamentals

See More
  • Market Capitalization, $K 41,991
  • Shares Outstanding, K 92,046
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,040 K
  • EBIT $ -4 M
  • EBITDA $ -4 M
  • 60-Month Beta 0.04
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 25.91
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.08
  • Most Recent Earnings $-0.02 on 11/26/25
  • Next Earnings Date 05/26/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4193 +13.43%
on 03/25/26
0.4829 -1.51%
on 04/07/26
+0.0587 (+14.08%)
since 03/13/26
3-Month
0.4086 +16.40%
on 03/13/26
0.5120 -7.11%
on 02/26/26
+0.0063 (+1.34%)
since 01/15/26
52-Week
0.4086 +16.40%
on 03/13/26
0.8000 -40.55%
on 09/16/25
-0.0044 (-0.92%)
since 04/15/25

Most Recent Stories

More News
NurExone to Participate in Water Tower Research Insights Conference on April 14, 2026

Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - April 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biotechnology company developing exosome-based...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Biologic’s U.S. Subsidiary Exo-Top and Florida-Based BioXtek Sign Strategic LOI for Exosome Manufacturing and Commercialization

TORONTO, Ontario and HAIFA, Israel and POMPANO BEACH, Florida, April 07, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”)...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Receives First Place in Healthcare at BOLD Awards VII and Engages Investor Brand Network to Support Awareness Strategy

TORONTO and HAIFA, Israel, April 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biotechnology company developing...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Strengthens U.S. Manufacturing Strategy Through Exo-Top Sublicense Agreement

TORONTO and HAIFA, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90)  (“ NurExone ” or the “ Company ”), a biotechnology company developing...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Announces Corporate Updates

TORONTO and HAIFA, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update

TORONTO and HAIFA, Israel, Feb. 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a biopharmaceutical company developing...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Biologic Advances Manufacturing and Regulatory Roadmap with Independent Batch Consistency Results for Exosome Production

Toronto, Ontario and Haifa, Israel--(Newsfile Corp. - February 10, 2026) - NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ("NurExone" or the "Company"), a biopharmaceutical company developing...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Appoints Eyal Gabbai to Board, Adding Large-Scale Healthcare System and Capital Markets Expertise

TORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) today announced changes to its board...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Reports Anti-Inflammatory Activity of Its Exosomes in Lab Analysis

TORONTO and HAIFA, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”) today announced new laboratory data...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)
NurExone Plans Small-Scale of ExoPTEN Clinical Manufacturing in Preparation for FUTURE First in Human USE Pathways

TORONTO and HAIFA, Israel, Dec. 12, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ” or the “ Company ”), a preclinical-biotechnology company...

NRX.VN : 0.650 (+3.17%)
NRXBF : 0.4756 (+4.25%)

Business Summary

NurExone Biologic Inc. is a pharmaceutical company which involved in developing a platform for biologically guided exosome-based therapies to be delivered, non-invasively, to patients who have suffered Central Nervous System injuries. The Company's principal product includes ExoPTEN. NurExone Biologic...

See More

Key Turning Points

3rd Resistance Point 0.4981
2nd Resistance Point 0.4869
1st Resistance Point 0.4812
Last Price 0.4756
1st Support Level 0.4643
2nd Support Level 0.4531
3rd Support Level 0.4474

See More

52-Week High 0.8000
Fibonacci 61.8% 0.6505
Fibonacci 50% 0.6043
Fibonacci 38.2% 0.5581
Last Price 0.4756
52-Week Low 0.4086

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.